Orserdu

Lilly's oral SERD Ember counts on Verzenio to broaden its glow

Lilly's imlunestrant monotherapy only mounted a PFS benefit in ESR1-mutated tumors, while its pairing with Verzenio moved the needle in a wider group.

Angus Liu Dec 11, 2024 8:15am